Furthermore, the combined therapy of double immune checkpoint inhibitors (ICIs), such as anti-PD1 and anti-CTLA4, with chemotherapy provoked strong systemic and intratumoral immune responses in BRCA1-mutated breast cancer [46]. Here, CTLA4 is linked to breast carcinoma.